Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Fiche publication
Date publication
juin 2017
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha
Tous les auteurs :
Tabone MD, Brugières L, Piperno-Neumann S, Selva MA, Marec-Bérard P, Pacquement H, Lervat C, Corradini N, Gentet JC, Couderc R, Chevance A, Mahier-Ait Oukhatar C, Entz-Werle N, Blay JY, Le Deley MC
Lien Pubmed
Résumé
Angiogenesis is essential for the progression and metastatic spread of solid tumours. Expression of vascular endothelial growth factor (VEGF) has been linked to poor survival among osteosarcoma patients but the clinical relevance of monitoring blood and urine angiogenic factors is uncertain. The aim of this study was to determine the prognostic significance of blood VEGF and blood and urinary basic fibroblast growth factor (bFGF) levels in osteosarcoma patients, both at diagnosis and during treatment.
Mots clés
Angiogenic factors, Basic fibroblast growth factor, Osteosarcoma, Vascular endothelial growth factor
Référence
BMC Cancer. 2017 Jun;17(1):419